ABVC Biopharma Inc
NASDAQ:ABVC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
ABVC Biopharma Inc
NASDAQ:ABVC
|
48.9m USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
44.1B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
267.6B CNY |
Loading...
|
|
| DE |
|
BioNTech SE
NASDAQ:BNTX
|
26.6B USD |
Loading...
|
|
| US |
|
United Therapeutics Corp
NASDAQ:UTHR
|
20.2B USD |
Loading...
|
|
| DK |
|
Genmab A/S
CSE:GMAB
|
126.9B DKK |
Loading...
|
|
| US |
|
Incyte Corp
NASDAQ:INCY
|
20.1B USD |
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
18.3B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
ABVC Biopharma Inc
Glance View
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for ABVC Biopharma Inc is -515.9%, which is above its 3-year median of -5 566.7%.
Over the last 3 years, ABVC Biopharma Inc’s Net Margin has increased from -5 732.4% to -515.9%. During this period, it reached a low of -43 076.5% on Mar 31, 2024 and a high of -342.8% on Mar 31, 2025.
